Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.36 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.33 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985328 | 0.90 | MAPT (0.44) | MAPTHTTALDH1A1POLBLMNA | |
| SCHEMBL9984371 | 0.88 | HTT (0.39) | MAPTHTTALDH1A1POLBTDP1 | |
| SCHEMBL9984257 | 0.88 | MAPT (0.41) | MAPTHTTALDH1A1POLBTDP1 | |
| SCHEMBL9987164 | 0.86 | TDP1 (0.42) | MAPTHTTALDH1A1POLBTDP1 | |
| SCHEMBL9984165 | 0.86 | MAPT (0.44) | MAPTHTTALDH1A1POLBTDP1 | |
| SCHEMBL9983279 | 0.84 | BRD4 (0.42) | MAPTHTTALDH1A1BRD4HSF1 | |
| SCHEMBL9984353 | 0.84 | HSF1 (0.51) | MAPTALDH1A1BRD4LMNASMN1; SMN2 | |
| SCHEMBL9983890 | 0.84 | MAPT (0.45) | MAPTALDH1A1POLBBRD4LMNA | |
| SCHEMBL9984258 | 0.83 | MAPT (0.40) | MAPTHTTALDH1A1POLBTDP1 | |
| SCHEMBL9984892 | 0.82 | HSF1 (0.41) | MAPTALDH1A1BRD4HSF1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | claimed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | claimed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | MAPT 4055/4885HTT 4749/4885ALDH1A1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.